Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials-Reference-Cited by-同舟云学术

Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials

Published:2019-03 Issue:3 Volume:7 Page:213-226
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Haworth Charles S,Bilton Diana,Chalmers James D,Davis Angela M,Froehlich Juergen,Gonda Igor,Thompson Bruce,Wanner Adam,O'Donnell Anne E

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference38 articles.

1. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis;Chalmers;Mol Immunol,2013

2. British Thoracic Society guideline for non-CF bronchiectasis;Pasteur;Thorax,2010

3. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study;Quint;Eur Respir J,2016

4. Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends;Ringshausen;PLoS One,2013

5. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006;Seitz;Chest,2010

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months;The Lancet Respiratory Medicine;2024-09

2. Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against Pseudomonas aeruginosa by Inhibiting Drug Efflux;Antibiotics;2024-08-26

3. Inhalable dry powder nano-formulations: advancing lung disease therapy-a review;Frontiers in Nanotechnology;2024-08-01

4. Reply to Chen et al.: Reexamining Chronic Obstructive Pulmonary Disease in Bronchiectasis: Elucidating Overdiagnosis and Outcomes from EMBARC’s ROSE Criteria;American Journal of Respiratory and Critical Care Medicine;2024-07-15

5. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC);American Journal of Respiratory and Critical Care Medicine;2024-07-01